{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:33Z","timestamp":1793946513722,"version":"4.8.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105499","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:25:14Z","timestamp":1784615114000},"page":"105499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Double-negative prostate cancer: Evolutionary mechanisms, microenvironmental remodeling, and clinical translation"],"prefix":"10.1016","volume":"226","author":[{"given":"Lei","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyun","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105499_bib1","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105499_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162148","article-title":"Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models","volume":"133","author":"Agarwal","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105499_bib3","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO-24-01989","article-title":"Phase I, first-in-human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer","volume":"43","author":"Aggarwal","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib5","article-title":"Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer","author":"Ashraf","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2026.105499_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2026.105499_bib7","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib8","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-18-0409","article-title":"A PDX\/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening","volume":"24","author":"Beshiri","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/1541-7786.MCR-24-0903","article-title":"Exploring STEAP1 expression in prostate cancer cells in response to androgen deprivation and in small extracellular vesicles","volume":"23","author":"Bizzaro","year":"2025","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105499_bib11","doi-asserted-by":"crossref","first-page":"S996","DOI":"10.1016\/j.annonc.2024.08.1735","article-title":"TAMARACK: randomized phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"de Bono","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib12","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105499_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146827","article-title":"Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer","volume":"6","author":"Brennen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2026.105499_bib14","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2021.39.15_suppl.2516","article-title":"A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors","volume":"39","author":"Burris","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105499_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/PO.20.00309","article-title":"Double-negative prostate cancer masquerading as a squamous cancer of unknown primary: a clinicopathologic and genomic sequencing-based case study","author":"Cackowski","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib16","article-title":"New insights into potential therapeutic targets for neuroendocrine prostate cancer: from bench to clinic","volume":"8","author":"Cai","year":"2025","journal-title":"Res. (Wash. D. C. )"},{"key":"10.1016\/j.critrevonc.2026.105499_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105499_bib18","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/1078-0432.CCR-22-3350","article-title":"Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN\/p53-deficient prostate cancer","volume":"29","author":"Chaudagar","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib19","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/s41467-021-26612-1","article-title":"Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer","volume":"12","author":"Che","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105499_bib20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s43018-022-00380-3","article-title":"Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer","volume":"3","author":"Cheng","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105499_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2026.105499_bib23","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/s41591-024-03204-2","article-title":"Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial","volume":"30","author":"De Laere","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105499_bib24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2159-8290.CD-22-0692","article-title":"Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes","volume":"13","author":"De Sarkar","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105499_bib25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","article-title":"Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation","volume":"14","author":"Franceschini","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105499_bib27","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0272","article-title":"ONECUT2: a validated drug target and lineage plasticity driver in prostate cancer and other malignancies","volume":"32","author":"Freeman","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105499_bib28","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib30","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","article-title":"Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer","volume":"81","author":"Ghoochani","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/acsmedchemlett.2c00481","article-title":"Selective Wee1 inhibitors led to antitumor activity in vitro and correlated with myelosuppression","volume":"14","author":"Guler","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.critrevonc.2026.105499_bib32","article-title":"Pathogenic genomic alterations in circulating tumor DNA predict overall survival in men with metastatic castrate-resistant prostate cancer","author":"Halabi","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110595","article-title":"Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis","volume":"39","author":"Han","year":"2022","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105499_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.955669","article-title":"Focus on the tumor microenvironment: a seedbed for neuroendocrine prostate cancer","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","article-title":"Transcriptional mediators of treatment resistance in lethal prostate cancer","volume":"27","author":"He","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105499_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039639","article-title":"Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma","volume":"10","author":"Heitmann","year":"2020","journal-title":"BMJ Open."},{"key":"10.1016\/j.critrevonc.2026.105499_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105499_bib38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/1078-0432.CCR-20-2380","article-title":"Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin lymphoma","volume":"27","author":"Hollebecque","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2026.105499_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1191311","article-title":"Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution","volume":"14","author":"Imamura","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2026.105499_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","article-title":"Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","volume":"7","author":"Jensen","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A phase I\/II trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105499_bib45","first-page":"9","article-title":"Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches","volume":"8","author":"Khorasanchi","year":"2025","journal-title":"Cancer Drug. Resist."},{"key":"10.1016\/j.critrevonc.2026.105499_bib46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41467-024-45489-4","article-title":"Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation","volume":"15","author":"Kim","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105499_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell."},{"key":"10.1016\/j.critrevonc.2026.105499_bib48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","article-title":"A phase 1\/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","volume":"129","author":"Kristeleit","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105499_bib49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105499_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175217","article-title":"Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer","volume":"134","author":"Ku","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105499_bib51","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.3390\/cancers13133325","article-title":"Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response","volume":"13","author":"Kukkonen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105499_bib52","doi-asserted-by":"crossref","first-page":"T51","DOI":"10.1530\/ERC-21-0002","article-title":"The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches","volume":"28","author":"Labrecque","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105499_bib53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pros.24630","article-title":"Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer","volume":"84","author":"Labrecque","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2026.105499_bib54","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105499_bib55","doi-asserted-by":"crossref","first-page":"S1188","DOI":"10.1016\/j.annonc.2022.07.1892","article-title":"Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)","volume":"33","author":"Lang","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41422-024-01025-z","article-title":"LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer","volume":"35","author":"Li","year":"2025","journal-title":"Cell. Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib57","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/2159-8290.CD-20-0387","article-title":"Metastasis and immune evasion from extracellular cGAMP hydrolysis","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105499_bib58","article-title":"Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer","author":"Li","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.critrevonc.2026.105499_bib59","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41586-025-09727-z","article-title":"NSD2 targeting reverses plasticity and drug resistance in prostate cancer","volume":"649","author":"Li","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105499_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.978","article-title":"The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer","volume":"12","author":"Lo","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105499_bib61","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","article-title":"The genomic and epigenomic landscape of double-negative metastatic prostate cancer","volume":"83","author":"Lundberg","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib62","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-24-1194","article-title":"Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors","volume":"24","author":"Ma","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105499_bib63","first-page":"2577","article-title":"Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors","volume":"41","author":"Marron","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/ijms26020679","article-title":"Clinical and genomic features of androgen indifferent prostate cancer","volume":"26","author":"Masur","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105499_bib65","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s43018-020-00141-0","article-title":"Accelerating precision medicine in metastatic prostate cancer","volume":"1","author":"Mateo","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105499_bib66","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/cells13231999","article-title":"Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer","volume":"13","author":"Maylin","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105499_bib67","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1038\/s41467-025-60654-z","article-title":"Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer","volume":"16","author":"Mizuno","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105499_bib68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","article-title":"EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer","volume":"2","author":"Morel","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105499_bib69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105499_bib70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-025-00854-4","article-title":"A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer","volume":"9","author":"Nauseef","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib71","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/1535-7163.MCT-23-0933","article-title":"AKT inhibition sensitizes to polo-like kinase 1 inhibitor onvansertib in prostate cancer","volume":"23","author":"Nouri","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105499_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.euo.2025.10.011","article-title":"PARP inhibitors in metastatic castration-resistant prostate cancer: rationale, mechanisms, and clinical applications","volume":"9","author":"Oudard","year":"2026","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib73","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/j.annonc.2023.09.1876","article-title":"Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: updated clinical and biomarker results from a phase I\/II study","volume":"34","author":"Patel","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib74","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2415308122","article-title":"Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer","volume":"122","author":"Pitzen","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105499_bib75","doi-asserted-by":"crossref","first-page":"ND03","DOI":"10.1158\/1538-7445.AM2025-ND03","article-title":"ABBV-969: a first-in-class dual-targeting PSMA-STEAP1 drug conjugate for the treatment of metastatic castrate-resistant prostate cancer","volume":"85","author":"Reilly","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib76","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2021.39.15_suppl.2517","article-title":"First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies","volume":"39","author":"Roohullah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib77","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105499_bib78","article-title":"Antibody-drug conjugates in prostate cancer: a systematic review","volume":"15","author":"Sardinha","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2026.105499_bib79","article-title":"Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): a randomized dose-expansion study","volume":"43","author":"Schweizer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib80","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105499_bib81","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-24-0890","article-title":"An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression","volume":"84","author":"Shrestha","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib82","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-026-01603-5","article-title":"A novel aurora kinase molecular glue-based degrader sp-2-067 inhibits prostate cancer cell growth and alters immune profile","author":"Shukla","year":"2026","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105499_bib83","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.21.00169","article-title":"Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer","volume":"39","author":"Sperger","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib84","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","article-title":"Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734","volume":"4","author":"Spriano","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105499_bib85","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","article-title":"The Polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression","volume":"36","author":"Su","year":"2019","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105499_bib86","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41417-024-00834-z","article-title":"Role of non-coding RNA in lineage plasticity of prostate cancer","volume":"32","author":"Tan","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105499_bib88","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1038\/s41598-022-08520-6","article-title":"Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer","volume":"12","author":"Tan","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105499_bib89","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105499_bib91","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2021-0051","article-title":"Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study","volume":"7","author":"T\u0103taru","year":"2021","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.critrevonc.2026.105499_bib92","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-2928","article-title":"A double-negative prostate cancer subtype is vulnerable to SWI\/SNF-targeting degrader molecules","author":"Thienger","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105499_bib93","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/ijms22020603","article-title":"The multifaced role of STAT3 in cancer and its implication for anticancer therapy","volume":"22","author":"Tolomeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105499_bib94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40170-020-00217-6","article-title":"Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer","volume":"8","author":"Tousignant","year":"2020","journal-title":"Cancer Metab."},{"key":"10.1016\/j.critrevonc.2026.105499_bib95","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105499_bib96","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00457","article-title":"Multicenter phase II study of olaparib and the ATR inhibitor ceralasertib in metastatic castration-resistant prostate cancer (TRAP)","author":"Tsung","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib97","first-page":"A212","article-title":"Biomarker analysis of magrolimab plus docetaxel in patients with 2L+ mNSCLC from ELEVATE-Lung and UC, a phase 2 multicohort study. J Immunother Cancer","volume":"12","author":"Van Buuren","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105499_bib98","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105499_bib99","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/genes13010135","article-title":"Expression of fibroblast activation protein is enriched in neuroendocrine prostate cancer and predicts worse survival","volume":"13","author":"Vlachostergios","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.critrevonc.2026.105499_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166647","article-title":"RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F\/ACSL4 axis","volume":"133","author":"Wang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105499_bib101","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105499_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2025.1737443","article-title":"Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors","volume":"5","author":"Wu","year":"2025","journal-title":"Front. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2026.105499_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1725097","article-title":"Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer","volume":"17","author":"Xiong","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib104","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12967-025-07053-6","article-title":"CBP\/p300, a promising therapeutic target for prostate cancer","volume":"23","author":"Xu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105499_bib105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105499_bib106","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cancers16020392","article-title":"ID2 promotes lineage transition of prostate cancer through FGFR and JAK-STAT signaling","volume":"16","author":"Zhang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105499_bib107","article-title":"Hes1 in malignant tumors: from molecular mechanism to therapeutic potential","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105499_bib108","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat. Genet."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:40:29Z","timestamp":1793943629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":108,"alternative-id":["S1040842826003860"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105499","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double-negative prostate cancer: Evolutionary mechanisms, microenvironmental remodeling, and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105499"}}